Our bespoke, iterative approach to radiotherapeutic design is fueled by a toolbox of technologies for peptide-based radiopharmaceuticals.

We are developing a robust pipeline of radiopharmaceuticals to address targets spanning solid and hematologic malignancies.

Backed by top-tier investors, our team has decades of expertise developing radiopharmaceuticals for highly targeted treatment of cancer.

Our executive team has a strong track record of growing successful life-sciences companies and our founders have decades of experience in peptide chemistry, cancer imaging, and radiopharmaceutical development.